In another trial, the use of everolimus, an mTOR inhibitor, on intellectual disability in children with tuberous sclerosis complex (TSC) revealed minimal improvement in cognitive functioning or other neuropsychological deficits in children with TSC [38]. The gene discussed is MTOR; the disease is tuberous sclerosis.